Identification
- Composition (DCI)
- téclistamab
- Manufacturer
- MAPHAR
- ATC code
- L01FX24
- Presentation
- Boite d'un flacon de 3 ml de solution
- Schedule / Reimb.
- A
- Hospital price
- 10425.00 MAD
Indications
TECVAYLI est indiqué en monothérapie, pour le traitement des patients adultes atteints d’un myélome multiple en rechute et réfractaire, ayant reçu au moins trois traitements antérieurs, incluant un agent immunomodulateur, un inhibiteur du protéasome et un anticorps anti-CD38 et dont la maladie a progressé pendant le dernier traitement.
Find an open pharmacy
On-call pharmacies near you
About TECVAYLI 10 MG / ML (30 MG / 3 ML)
TECVAYLI 10 MG / ML (30 MG / 3 ML) is marketed in Morocco by MAPHAR and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of TECVAYLI 10 MG / ML (30 MG / 3 ML), consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about TECVAYLI 10 MG / ML (30 MG / 3 ML)
Answers to common questions from Moroccan patients about this drug.